Strengthening Community-Driven Care
Supports projects embedding certified medical education within implementation strategies to improve evidence-based care for relapsed/refractory multiple myeloma in community healthcare settings.
Funder: Johnson & Johnson (Janssen)
Due Dates: June 30, 2026 (RRMM - bispecific antibody) | July 15, 2026 (RRMM - CAR T)
Funding Amounts: Up to $275,000 per project; projects up to 18 months; lower cost proposals prioritized; no institutional overhead, salaries, or equipment costs permitted.
Summary: Supports implementation science projects embedding certified medical education to improve care for relapsed/refractory multiple myeloma in community settings.
Key Information: Research-only proposals are not eligible; CME/CE-accredited organizations must submit.
Description
Johnson & Johnson (Janssen) is offering implementation science grants to support independent medical education initiatives aimed at optimizing the treatment and care of patients with relapsed/refractory multiple myeloma (RRMM). These grants specifically fund projects that embed certified continuing medical education (CME/CE) within broader implementation strategies, targeting practice-level or system-level changes that improve adoption and sustainability of evidence-based therapies—either bispecific antibodies (BsAb) or CAR T-cell therapy—in community healthcare settings. The program is designed to address real-world barriers, foster multidisciplinary collaboration, and drive measurable improvements in clinician behavior, care processes, and patient outcomes, particularly in communities facing inequities in healthcare access.
